Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12567MR)

This product GTTS-WQ12567MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12567MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4434MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ10669MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ1295MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ10130MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ8863MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ858MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ4440MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ14087MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW